A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients
Sara Rossi(University of Siena), Giuseppe Campiani(University of Siena), Cosima T. Baldari(University of Siena), Stefania Butini(University of Siena), Katia Varani(University of Ferrara), Vanessa Tatangelo(University of Siena), Maria Dichiara(University of Siena), Alessandro Gozzetti(University of Siena), Silvia Pasquini(University of Ferrara), Monica Bocchia(University of Siena), Giuseppe Marotta(Ospedale Santa Maria alle Scotte), Ludovica Lopresti(University of Siena), Fabrizio Vincenzi(University of Ferrara), Simone Brogi(University of Pisa), Chiara Carrara(University of Siena), Gabriele Carullo(University of Siena), Laura Patrussi(University of Siena), Sandra Gemma(University of Siena), Martina Cappello(University of Ferrara), Margherita Malchiodi(University of Siena)
Cited by 9
Related Papers
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|996
Pharmacology of Adenosine Receptors: The State of the Art
|Physiological Reviews|2018|750
The <i>Helicobacter pylori</i> Vacuolating Toxin Inhibits T Cell Activation by Two Independent Mechanisms
|The Journal of Experimental Medicine|2003|303